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Estrogen Inhibits Calcification of VSMCs via Promotion of
Autophagy
Xiong Dan, Yuan LinQin. The Second XiangYa Hospital, Central
South University, ChangSha, China
Background: Medial artery calcification is an active cell-regulated
process that involves the differentiation of vascular smooth muscle
cells (VSMCs) to an osteoblast-like phenotype. Autophagy is a highly
regulated homoeostatic process involved in the lysosomal degradation
of damaged cell organelles and proteins, which considered an impor-
tant pro-survival mechanism under diverse stress conditions. Arterial
calcification and osteoporosis are both associated in postmenopausal
women. Estrogen is a key therapeutic method for postmenopausal
osteoporosis and is contribute to decrease the coronary-artery calcium
and can promote the autophagy of endothelial cell and VSMC via
EReERKemTOR signaling pathway. But autophagy, as well as the
contribution of estrogen to vascular calcification, is poorly
understood.
Objective: To clarify the effect and the mechanism involved in
estrogen on autophagy and calcification of VSMCs.
Methods: Primary mouse VSMCs were treated with b glycero-
phosphate to induce calcification. Estrogen was incubated with
VSMCs during osteoblatic differentiation. Inhibitors to the following
estrogen receptors were used: estrogen receptor alpha (ERa), estro-
gen receptor beta (ERb), combined ERa and ERb (ERab).3MA or
knock down of ATG5 were selected to block autophagy, rapamycin
(pmTOR) was used to promote autophagy. Runx2 was analyzed by
western blot and ALP activity was measured to study the effect of
estrogen on osteoblastic differentiation. Ultrastructural analysis,
GFP-LC3 redistribution, expression of LC3I/II and ATG5 detected
by western blot were employed to determine the presence of autoph-
agy analysis in VSMCs.
Results: 1. Estrogen reduced the expression of RUNX2 of VSMCs
mainly through ERa but not ERb in the osteogenic medium; 2. Estro-
gen enhanced the autophagy of VSMCs during the process of osteo-
genic differentiation: Estrogen increased the level of the lipid
-conjugate form of the autophagosome marker light-chain 3-II
(LC3II) and ATG5 in VSMCs. Treatment with rampamicin, an
inducer of autophagy, Estrogen further increased the LC3II and
ATG5 level. Estrogen also increased the number of LC3 puncta
tagged with green fluorescent protein (GFP); Electron microscopy
of typical autophagic structures were increased in VSMCs treated
with estrogen. 3. Estrogen inhibited the calcification of VSMC via
enhancing autophagy. Inhibition of autophagy with 3MA or knockingdown ATG5, the expression of RUNX2 was increased compared with
those only treated with estrogen. Furthermore, the expression of
runx2 was further decreased in the VSMCs treated with estrogen
and rampamicin together.
Conclusion: Estrogen inhibits calcification of VSMC via promo-
tion of autophagy through the ERaemTOR signaling pathway.
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Antiosteoporotic Activity of Dihydrophaseic Acid 30-O-b-D-Gluco-
pyranoside Derivatives from Lycii Radicis Cortex
Eunkuk Park 1,2, Mun-Chang Kim 1,2, Chun Whan Choi 3, Vit-
Na Choi 1,2, Ji-Won Lee 4, Jin-Hyok Park 5, Dam Huh 5, Seon-
Yong Jeong 1,2. 1 Department of Medical Genetics, Ajou University
School of Medicine, Suwon, Republic of Korea 2 Department of
Biomedical Sciences, Ajou University Graduate School of Medicine,
Suwon, Republic of Korea 3 Natural Products Research Institute,
Gyeonggi Institute of Science & Technology Promotion, Suwon,
Republic of Korea 4 Korea Food Research Institute, Seongnam,
Republic of Korea 5 Dongwoodang Pharmacy Co., Ltd, Yeongchen,
Republic of Korea
Objective: Our previous study demonstrated that ethanol extract of
Lycii Radicis Cortex (LRC) prevented the ovariectomized-induced
bone mineral density loss in mice via promoting the differentiation
of osteoblast linage cells. A single compound, D3G, was isolated
from the LRC extract as a candidate component enhancing bone
formation. The aim of this study was to investigate the antiosteopor-
otic effects of dihydrophaseic acid 3ʹ-O-b-D-glucopyranoside
(D3G).
Methods: The 70% ethanol extract of LRC was evaporated, sus-
pended in H2O, and then partitioned successively with CH2Cl2,
EtOAc, n-BuOH, and aqueous fractions. Fractionation of the LRC
extract was performed to identify the bioactive compound(s) respon-
sible for the bone formation-enhancing effect of LRC extract. The
structure of the isolated compound was elucidated by 1H-NMR,
13C-NMR, and mass spectrometry analyses. To confirm the bioactiv-
ity of the isolated single compound, three different concentrations (1,
5, and 10 mg/ml) of the compound were treated in the osteoblastic cell
lines C3H10T1/2 and MC3T3-E1, and alterations in the ALP activity
of the cells were examined
Results: The highest alkaline phosphatase activity was observed
with 5 mg/ml of D3G in both cell lines: C3H10T1/2 and MC3T3-
E1. The D3G treatment for 21 days increased the mineralized nodule
formation in the MC3T3-E1 cell line. The expression of osteoblastic
markers, Alpl, Runx2, and Bglap, was significantly increased in the
138 Abstracts for poster (basic) sessions / Osteoporosis and Sarcopenia 1 (2015) 137e139D3G-treated cells compared to the non-treated control cells. The D3G
treatment did not influence osteoclast differentiation in primary-cul-
tured monocytes of mouse bone marrow. In coculture of monocytes
and MC3T3-E1 cells, however, D3G induced both osteoblast and
osteoclast differentiation.
Conclusions: This study demonstrated that D3G increased the
proliferation and differentiation of osteoblast cells and enhanced
bone formation. These results suggest that D3G may be a good can-
didate for the treatment of osteoporosis
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Effect of ONO-0980250, a Cathepsin K Inhibitor, on Arthritis and
Bone Mineral Density in Rats with Collagen-Induced Arthritis
Takahiro Yamashita, Hiroshi Hagino, Hideki Nagashima. Tottori
University, Yonago, Tottori, Japan
Objectives: Cathepsin K expressed by osteoclasts and synovial
fibroblasts degrades key components of bone and cartilage, such
as type I and type II collagen, osteonectin, and aggrecan. Inhibition
of cathepsin K protease activity may be beneficial for prevention of
bone erosion and cartilage degradation in rheumatoid arthritis
(RA). The CIA rat model is an established model for studying
the pathology and treatment of RA. We studied the effect of
ONO-KK1-300-01(ONO), a cathepsin K inhibitor, on arthritis and
bone mineral density (BMD) in rats with collagen-induced arthritis
(CIA).
Methods: Seven-month-old female Sprague - Dawley rats were
divided into five groups: rats without CIA (CNT), CIA rats that
underwent ovariectomy (OVX) and were treated with ONO
(CIA + OVX + ONO), CIA rats that underwent OVX and were treated
with vehicle (CIA + OVX + Veh), CIA rats that underwent sham sur-
gery and were treated with ONO (CIA + sham + ONO), and CIA rats
that underwent sham surgery and were treated with vehicle
(CIA + sham + Veh). ONO was orally administered at a dose of
15 mg/kg daily for 4 weeks, beginning initial sensitization until death
at 4 weeks. Every week until death, we evaluated the hind paw thick-
ness and arthritis score. Hind paw thickness was evaluated by meas-
uring the ankle width from the medial malleolus to the lateral
malleolus using a constant - tension caliper. Arthritis was evaluated
according to the degree of severity and the extent of erythema and
edema of the periarticular tissue, scored as 0e3 points. The arthritis
score was the sum of the scores for the digit, metacarpophalangeal,
and wrist joints in the forepaw and the ankle joint in the hind paw.
BMD was measured by bone densitometry at the distal metaphysis
and the diaphysis of the femur.
Results: ONO administration suppressed the hind paw thickness
and arthritis score and prevented decrease in BMD. The
CIA + OVX + Veh group had the highest arthritis score. The hind
paw thickness and arthritis score in the CIA + OVX + Veh group
was significantly different from than in the CIA + OVX + ONO
group.
Although the CIA + OVX + Veh group did not show significant
decrease in BMD compared with the CIA + sham + Veh group, the
CIA + sham + ONO group showed a significantly high score in
BMD compared with the CIA + sham + Veh group.Conclusion: Our findings indicate that, in an animal model of
arthritis, cathepsin K inhibitors can prevent bone loss and arthritis.0045
A Role of RACK1 in RANKL-Induced Osteoclastogenesis
Jingjing Lin, Soo Young Lee. Ewha Womans University, Seoul,
Republic of Korea
Objectives: The TRAF6-TAK1 axis is a key component of the NF-kB
and MAPK signaling pathways in response to various stimuli. How-
ever, the stimulus-specific control mechanism of the TRAF6-TAK1
axis has remained elusive.
Method: To examine the role of RACK1 in vitro, we have tried to
test RACK1 gain-of function and loss-of function analyses in primary
bone marrow-derived monocytes/macrophages or RAW264.7 cells.
Furthermore, to test RACK1's knockdown in vivo, we have injected
RACK1 siRNA into mice calvaris.
Results and conclusions: RACK1 gain-of function and loss-of
function analyses indicated that RACK1 is necessary for osteoclast
differentiation through the promotion of p38 activation. RACK1 asso-
ciated with multiple components of the RANK-mediated p38 path-
way, including RANK, TRAF6, TAK1, and MKK6, thereby leading
to the activation of the MKK6-p38 pathway. Importantly, knockdown
studies of RACK1 and TAK1 demonstrated that RACK1 acted as a
bridge for the bonding of MKK6 to the TRAF6-TAK1 complex. Fur-
thermore, local administration of RACK1 siRNA into mice calvarias
was found to decrease the RANKL-induced bone loss by reducing the
numbers of osteoclasts. These findings suggest that RACK1 plays an
important role in RANKL-induced p38 activation by facilitating the
association of MKK6 with TAK1, and may provide a molecular target
for a new therapeutic strategy.0061
Establishment of Osteoporosis Model in C57/BL6 Mice by
Ovariectomy
Yue Ding, Guangtao Fu, Changchuan Liu, Shixun Liu. Sun Yat-Sen
University, Sun Yat-Sen Memorial Hospital, Guangzhou, China
Objective: To investigate the optimum timing and how long did it
cost to build the osteoporosis model in C57/BL6 mice by ovariectomy
(OVX).
Methods: 50 six-week-old female C57/BL6 mice were divided
into 10 groups (A-J). Group A and F underwent BMD measurement
by DEXA on cranium in eight-week-old and twelve-week-old,
respectively. The BMD analysis of group B-E was performed in 8
weeks, 10 weeks, 12 week and 14 weeks after the mice underwent
OVX in eight weeks old. The BMD analysis of group G-J was per-
formed in 6 weeks, 8 weeks, 10 week and 12 weeks after the mice
underwent OVX in twelve weeks old.
Results: The mean BMD on cranium of twelve-week-old
mice(0.131 ± 0.030g/cm2) was significantly higher than the BMD
of eight-week-old mice(0.113 ± 0.042 g/cm2) (p < 0.05). There
was no significant difference between group AeE. The mean BMD
on cranium of group F(0.131 ± 0.030 g/cm2) was significantly higher
than the BMD of group H(0.113 ± 0.014g/cm2) (p < 0.05). And the
BMD decreased smoothly from H-J (p > 0.05).
Conclusions: The optimum age to build up the osteoporosis
model in C57/BL6 mice is twelve weeks old, and we should wait
at least 8 weeks before the model is established.
